Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling US$1.8 billion, it said on Friday.
Denmark’s Novo Nordisk to buy Emisphere Technologies in US$1.8 billion deal
